Jubilant Ingrevia Ltd (JUBLINGREA) Q1 FY27 Results Analysis: EBITDA Jumps 37%, Specialty Margins Compress

Jubilant Ingrevia Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 1,300.27 Cr (+25.28% YoY) and PAT growth of +40.91% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Q1FY27 was a strong quarter with record revenue of Rs.1,300 Cr (+25% YoY) and EBITDA of Rs.209 Cr (+37% YoY). Chemical Intermediates staged a dramatic turnaround with EBIT up 8.8x, while Specialty Chemicals margin compression and rising finance costs are watch items. The company is well on track to meet its FY27 EBITDA growth guidance of ≥20%.

Key Investment Insights

Key Positives

• Revenue reached a record Rs.1,300.27 Cr, up 25.28% YoY
• EBITDA grew 36.53% YoY to Rs.209.30 Cr, with margin expanding 133 bps to 16.10%
• PAT grew 40.91% YoY to Rs.105.82 Cr, EPS up 41.05% to Rs.6.70
• Chemical Intermediates segment EBIT surged 8.8x to Rs.43.97 Cr, margin from 1.30% to 8.39%
• All three segments reported YoY revenue growth (Specialty +11.38%, Nutrition +36.25%, Chemical Intermediates +37.60%)
• Standalone PAT grew 113.9% YoY to Rs.126.22 Cr

Risk Factors

• Specialty Chemicals EBIT margin compressed from 22.21% to 20.49% YoY due to pricing pressure
• Finance costs increased 37.35% YoY to Rs.17.43 Cr, driven by higher borrowings
• Working capital build of Rs.153.16 Cr in inventory, current ratio declined to 1.24 from 1.29
• Promoter pledge increased to 4.206% of capital (from 3.452% previously)
• Subsidiaries (including newly acquired Remidex Pharma) were a net drag of Rs.20.40 Cr on consolidated PAT